Skip to main content
SpringerLink
Log in

Advances in platinum cancer chemotherapy

Advances in the design of cisplatin analogues

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

In the past 4 years substantial progress has been made in the development of platinum cancer chemotherapy. A number of drug candidates have undergone clinical trials and one ‘second generation’ platinum drug, carboplatin, has been approved for use in the treatment of ovarian and small cell lung cancer. This review covers the major developments since the last international conference on Platinum Chemotherapy in Vermont, and attempts to highlight the primary factors that appear to be influencing the synthesis and screening of potential third generation platinum drugs.

A predominant feature in the evaluation of analogues has been the emphasis on chelating diamine complexes, in particular those of diaminocyclohexane, which show activity in L1210 tumours that are resistant to cisplatin, and the use of a wide range of carboxylate ligands as a means of circumventing solubility and toxicity problems inherent in the parent compounds. There has also been an increased effort in studies relating to complexes containing mixed amines and functionalised amines, building on the assumption, which remains valid to date, that two amines are a necessary requirement for anti-tumour activity. Efforts have also been made to address the use of complexes containing biologically active ligands, and the concept of targeting compounds to specific organs and formulating drugs to achieve more specific activity or controlled release of drugs with lower toxicities. These may provide a viable route to drugs that can be administered more easily, for example by an oral route, or show a different spectrum of activity. However, it may prove difficult to adequately characterise these more complex systems.

The major problem encountered in evaluating cisplatin analogues, as with other prospective cancer drugs, is finding reproducible anti-tumour screens that are predictive of the behaviour of the drugs in the clinic. Progress is being made in the development of sensitive and resistant human tumour xenograft lines and this area should be monitored with interest, as it may provide a key to the development of a future platinum drug, hopefully with a wider range of activity than either cisplatin or carboplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosenberg B, Van Camp L, Trosko JE, Mansour VH: Platinum compounds: A new class of potent antitumour agents. Nature 222: 385, 1969

    Google Scholar 

  2. Cleare MJ: Transition metal complexes in cancer chemotherapy. Coord Chem Rev 12: 349, 1974

    Google Scholar 

  3. Braddock PD, Connors TA, Jones M, Khokhar AR, Melzack DH, Tobe ML: Structure and activity relationships of platinum complexes with antitumour activity. Chem-Biol. Interact 11: 145, 1975

    Google Scholar 

  4. Cleare MJ, Hoeschele JD: Studies on the antitumour activity of group VIII transition metal complexes. Part 1. platinum II complexes. BioInorg Chem 77: 187, 1973

    Google Scholar 

  5. Cleare MJ, Hydes PC: Antitumour properties of metal complexes. In: Sigel H (ed) Metal Ions in Biological Systems, Marcel Dekker Inc., New York 1980, 2: 1

    Google Scholar 

  6. Hydes PC: Synthesis and testing of platinum analogues — an Overview. In: Hacker MP, Douple EB, Krakoff IH (eds) Platinum Coordination Complexes in Cancer Chemotherapy, Martinus Nijhoff, Boston, 1984, 216: Cleare MJ: ibid: 213

    Google Scholar 

  7. Harrap KR: Platinum analogues: Criteria for selection. In: Maggia FM (ed) Cancer Chemotherapy, Martinus Nijhoff, Boston 1983, 1: 172

    Google Scholar 

  8. Roberts JJ, PeraJr MF: DNA as a target for anticancer coordination compounds. ACS Symp Ser 209: 3, 1983

    Google Scholar 

  9. Reedijk J: Nomenclature for platinum antitumour compounds. In: Hacker MP, Douple EB, Krakhoff IH (eds): Platinum Coordination Complexes in Cancer Chemotherapy, Martinus Nijhoff, Boston, 1984, p.3

    Google Scholar 

  10. Caradonna JP, Lippard SJ, Gait MJ, Singh M: The antitumor drug cis [Pt(NH3)2Cl2)] forms an intrastrand d(GpG) cross-link upon reaction with [d(ApGpCpCpT)]2 J Am Chem Soc 104: 5793, 1982

    Google Scholar 

  11. Marcelis ATM, den Hartog JHJ, Reedijk J: Intrastrand cross-linking of the guanines of the deoxytrinucleotide d(G-C-G) via eis Pt(NH3)2Cl2. J Am Chem Soc 104: 2664, 1982

    Google Scholar 

  12. den Hartog JHJ, Altona C, Chottard J-C, Girault J-P, Lallemand J-Y, de Leeuw FAAM, Marcelis ATM, Reedijk J: Conformational analysis of the adduct cis-(PT (NH3)2D (GPG) + in aqueous solution. A high field (500–300 MHZ) nuclear magnetic resonance investigation. Nucl Acids Research, 10: 4715, 1982

    Google Scholar 

  13. Girault J-P, Chottard J-C, Guittet ER, Lallemand J-L, Huynh-Dinh T, Igolen J: Specific platinum chelation by the guanines of the deoxyhexanueleotide d(T-G-G-C-C-A) upon reaction with cis [Pt(NH3)2 (H2O)2] (NO3)2. Biochem and Biophys Research Commun 109: 1157, 1982

    Google Scholar 

  14. Van Hemelryck B, Guittet E, Chottard G, Girault J-P, Huynh-Dinh T, Lallemand J-Y, Igolen J, Chottard J-C: A d(GpG)-platinated oligonucleotide can form a duplex with a complementary strand. J Am Chem Soc 107: 4916, 1985

    Google Scholar 

  15. Reily MD, Marzilli LG: Anti-cancer platinum drug adducts with AMP. Novel direct proton and platinum-195 evidence for slowly interconverting head-to-tail rotamers. Potential role of amine ligand bulk and amino groups in guanine selectivity and anticancer activity. J Am Chem Soc 107: 4916, 1985

    Google Scholar 

  16. Fichtinger-Schepman AMJ, Lohman PHM, Reedijk J: Detection and quantification of adducts formed upon interaction of diammine dichloroplatinum (II) with DNA by anion-exchange chromatography after enzymatic degradation. Nucl Acids Research 10: 5345, 1982

    Google Scholar 

  17. Eastman A: Characterisation of the adducts produced in DNA by cis-diammine dichloroplatinum (II) and cis-dichloro (ethylenediamine) platinum (II). Biochemistry 22: 3927, 1983

    Google Scholar 

  18. Butour J-L, Johnson NP: Chemical reactivity of mono-functional platinum-DNA adducts. Biochemistry 25: 4534, 1986

    Google Scholar 

  19. Micetich KC, Barnes D, Erickson LC: A comparative study of the cytotoxicity and DNA-damaging effects of cis (Diammine) (1,1 cyclobutane dicarboxylato) — platinum (II) and cis Diammine dichloroplatinum (II) on L1210 cells. Cancer Res 45: 4043, 1985

    Google Scholar 

  20. Sherman SE, Gibson D, Wang AH-J, Lippard SJ: X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(dpGpG)]. Science 230: 412, 1985

    Google Scholar 

  21. Cleare MJ, Hydes PC, Malerbi BW, Watkins DM: Anti-tumour platinum complexes: Relationships between chemical properties and activity. Biochimie 60: 835, 1970

    Google Scholar 

  22. Barnard CFJ, Cleare MJ, Hydes PC: Second generation anticancer platinum compounds. Chemistry in Britain (November): 1001, 1986

  23. Boven E, Van der Vigh WJF, Nauta MM, Schluper HMM, Pinedo HM: Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res. 45: 86, 1985

    Google Scholar 

  24. Winograd B, Vermoken JB, ten Bokkel Huinink WW, Simonetti G, Gall HE, Tish Knobf MK, Van der Vijgh WJF, McVie JG, Pinedo HJM: Phase I study of ethylenediamine platinum (II) malonate NSC-14068 A second generation platinum analogue. Cancer Res 46: 2148, 1986

    Google Scholar 

  25. Cutbush SD, Kuroda R, Neidle S, Robins AB: The anti-tumour complex Ethylenediamine platinum (II) malonate: X-ray structure analysis and studies on its stability in solution. J Inorg Biochem 18: 213, 1983

    Google Scholar 

  26. Connors TA, Jones M, Ross WCJ, Braddock PD, Khokhar AR, Tobe M: New platinum compounds with anti-tumour activity. Chem Biol Interact 5: 415, 1972

    Google Scholar 

  27. Gale GR, Walker EMjr, Atkins LM, Smith AB, Meischen SJ: Auntileukaemic properties of (dichloro)(2,2 diamino-cyclohexane) platinum (II). Res Commun Chem Pathol Pharmacol 7: 529, 1974

    Google Scholar 

  28. Bruck MA, Bau R, Noji M, Inagaki K, Kidani Y: The crystal structure and absolute configurations of the anti-tumor complexes Pt (oxalato) (1R, 2R-cyclohexane-diamine and Pt (malonato) (1R, 2R-cyclohexanediamine). Inorg Chim Acta 92: 279, 1984

    Google Scholar 

  29. Mathe G, Kidani Y, Noji M, Moral C, Bourut C, Chenu E: Anti-tumour activity of 1-OPH in mice. Cancer Lett 27: 135, 1985

    Google Scholar 

  30. Nakayama Y, Iwata K, Takahashi K: GB Patent, 2148891A, 1985

  31. Berg J, Bulten EJ, Verbeek F: GB Patent: 2093845A, 1982

  32. Verbeek F, Berg J, Bulten EJ: GB Patent, 2128651A, 1984

  33. Craciunescu DG, Searcia V, Furlani-Candiani A, Doadrio A, Ghirvu C, Ravalico L: On the synthesis, cytostatic and antitumour properties of new platinum (II) complexes with 1,2 diamino cyclopentane. J Pharm Belg 41: 286, 1986

    Google Scholar 

  34. Boven E, Nauta MM, Schluper HMM, Van der Vijgh WJF, Pinedo HM: Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice. Eur J Cancer Clin Oncol 21: 1253, 1985

    Google Scholar 

  35. Noji M, Gohchi Y, Kidani Y: Preparation of antitumor platinum (II) complexes of 1,2 diphenylethylene diamine isomers and their interactions with DNA and its purine moieities. Chem Biol Interactions 51: 37, 1984

    Google Scholar 

  36. Tsujihara K, Morikawa T, Takeda M, Arai Y: European Patent: 0115929A, 1984

  37. Noji M, Motoyama S, Tashiro T, Kidani Y: Synthesis and antitumour activity of Pt (II) complexes containing 2,3-Diaminopropanol isomers. Chem Pharm Bull 31: 1469, 1983

    Google Scholar 

  38. Sosnovsky G, Lukszo J: In the search for New Anticancer drugs VII. J Cancer Res Clin Oncol 107: 217, 1984

    Google Scholar 

  39. Hlavka JJ, Bitha P, Lin YI: European Patent: 0146711, 1985

  40. Bradner WT, Rose WC, Huftalen JB: Antitumor activity of platinum analogues. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin: Current Status and New Developments. Academic Press, New York, 1980, p. 171

    Google Scholar 

  41. Rochon FD, Kong P-C: GB Patent: 2137198A, 1984

  42. Presnov MA: GB Patent: 2163163A, 1984

  43. Pointeau P, Patin H, Rumin R, Letourneux Y, Chesne C, Roussakis C: Synthesis and structure of platinum (II) (aminophenol) (pyridine) complexes. Eur J Med Chem 20: 327, 1985

    Google Scholar 

  44. Speer RJ, Ridgway H, Hall LM, Stewart DP, Howe KE, Lieberman DZ, Newman AD, Hill JM: Coordination complexes of platinum as antitumour agents. Cancer Chemother Reports 59: 629, 1975

    Google Scholar 

  45. Bersanetti E, Pasini A, Pezzoni G, Protesi G, Savi G, Supino R, Zunino F: Antitumor complexes of platinum with carrier molecules. 2. Mixed complexes of amino acids with tert-butylamine. Inorg Chim Acta 93: 167, 1984

    Google Scholar 

  46. Amundsen AR, Stern EW: European Patent: 098135A, 1983

  47. Noji M, Motoyama S, Tashiro T, Kidani Y: Synthesis and antitumor activity of platinum (II) complexes containing 2,3-diaminopropanol isomers. Chem. Pharm Bull 31: 1469, 1983

    Google Scholar 

  48. Spassovska N Ch, Grancharov K Ch, Maneva L St, Popov TA, Spassovski M Ch, Golovinsky EV, Tsanec RG: Anti-bacterial and antitumour activity of a spermine platinum (II) complex. Pro Int Congr Chemother 13th 17: 281, 1983

    Google Scholar 

  49. Craciunescu D, Furlani A, Searcia V, Ghirvu C, Doadrio A: On the synthesis, cytostatic and antitumor properties of new Pt (II) and Pt (IV) complexes with chloroanilines. Chem Biol Interactions 53: 45, 1985

    Google Scholar 

  50. Soln T, Matsumoto K, Fuwa K: Syntheses, antitumour activities and toxicities of platinum (II) complexes containing piperidine and morpholine derivatives. Inorg Chim Acta 65: L171, 1982

  51. Harrison RC, McAuliffe CA, Friedman ME: In vivo properties of some new cis-platinum complexes containing 7-azaindole ligands. Inorg Chim Acta 92: 43, 1984

    Google Scholar 

  52. Hlavka JJ, Bitha P, Lin Y: U S Patent: 4544, 544, 759, 1985

  53. Hlavka JJ, Bitha P, Lin Y: U S Patent: 4, 546, 181, 1985

  54. Maeda M, Abiko N, Uchida H, Sasaki T: Synthesis and antitumor activity of cis-dichloroplatinum (II)-N-Aminated nucleoside complexes. J Med Chem 27: 444, 1984

    Google Scholar 

  55. Maeda M, Abiko N, Uchida H, Sasaki T: Synthesis and antitumor activity of platinum (II) complexes of N-amino-nucleosides. Nucl Acids Research: 131, 1982

  56. Brown DB, Khokhar AR, Hacker MP, McCormack JJ, Stalick WM: Synthesis and antitumour activity of platinum complexes containing neutral and protonated amino-olefin ligands. Inorg Chim Acta 67: 45, 1982

    Google Scholar 

  57. Butour J-L, Mazard AM, Macquet JP: Kinetics of the reaction of cis-platinum compounds with DNA in vitro. Biochem and Biophys Res Commun 133: 347, 1985

    Google Scholar 

  58. Khokhar AR, Krakoff IH, Hacker MP, McCormack JJ: The synthesis and antitumor properties of a series of water soluble carboxylato (1, 2 diamino cyclohexane) platinum (II) complexes. Inorg Chim Acta 108: 63, 1985

    Google Scholar 

  59. Brown DB, Khokhar AR, Hacker MP, McCormack JJ: European Patent: 0130482A, 1985

  60. Maeda M, Uchida NA, Sasaki T: Liposoluble platinum (II) complexes with antitumour activity. Japan J Cancer Res 77: 523, 1986

    Google Scholar 

  61. Newman RA, Khokhar AR, Sunderland BA, Travis EL, Bulger RE: A comparison in rodents of renal and intestinal toxicity of cisplatin and a new water-soluble antitumour platinum complex N-methylimino diacetato diaminocyclohexane platinum (II). Toxicol Appl Pharmacol 84: 454, 1986

    Google Scholar 

  62. Khokhar AR, Hacker MP, McCormack JJ, Krakoff IH: Pharmacological, toxicological and chemical studies on water soluble iminodiacetato-1,2-diaminocyclohexane platinum (II). IUPHAR, 9th Intl Congress of Pharmacology: 1365, 1984

  63. Khokhar AR, Newman RA: Development of a ‘third generation’ of antitumor platinum compounds. Cancer Bull 37: 179, 1985

    Google Scholar 

  64. Khokhar AR, Hacker MP, McCormack JJ, Krakoff IH, Brown DB: Antitumor and toxicity studies on water soluble N-substituted iminodiacetato-1,2-diaminecyclohexane. Proc Amer Assoc Cancer Res 26: 262, 1985

    Google Scholar 

  65. Speer RJ, Stewart DP: European Patent: 0155705A, 1985

  66. Kidani Y: European Patent: 00981121A, 1983

  67. Kidani Y, Achiwa K, Ono H, Tomatsu K, Zaikokuj K, Noji M, Tashiro T: Antitumor activities and stability of monochloro (d-glucuronato) (1R, 2R-cyclohexanediamine) platinum (II). J Clin Hematol and Oncol 15: 35, 1985

    Google Scholar 

  68. Totani T: GB Patent: 2091731A, 1982

  69. Kidani Y: European Patent: 0136012, 1985

  70. Meischen SJ, Gale GR, Lane LM, Fraugakis CJ, Rosenblum MG, WalkerJr EM, Atkins LM, Smith AB: Antileukemic properties of organoplatinum compounds. J Nat Cancer Inst 57: 841, 1976

    Google Scholar 

  71. Speer RJ, Stewart D, Ridgway H: Preclinical evaluation of bis (pyruvato)-1,2 diaminocyclohexaneplatinum (II) as a potential antitumor agent. J Clin Hematol and Oncol 13: 89, 1983

    Google Scholar 

  72. Totani T, Shiratori O, Aono KE: European Patent: 0166366A, 1986

  73. Amundsen AR, Stern EW: US Patent: 4, 505, 928, 1985

  74. Totani T, Aono K: GB Patent: 2, 140, 804A, 1984

  75. Hollis LS, Amundsen AR, Stern EW: Synthesis, structure and antitumor properties of platinum complexes of vitamin C. J Am Chem Soc 107: 274, 1985

    Google Scholar 

  76. Hacker MP, Khokhar AR, Brown DB, McCormack JJ, Krakoff IH: Ascorbato (1,2-diaminocyclohexane): platinum (II) complexes. A new series of water-soluble antitumor drugs. Cancer Res 45: 4748, 1985

    Google Scholar 

  77. Amundsen AR, Stern EW: US Patent: 4, 457, 926, 1984: US Patent: 4, 462, 998, 1984

  78. Ribaud P, Gouveia J, Misset JL, Mathe G: Phase I study of cis-dichloro trans-dihydroxy-bis (isopropylamine) platinum IV, CHIP. Oncology 43: 78, 1986

    Google Scholar 

  79. Bramwell VHC, Crowther D, O'Malley S, Swindell R, Johnson R, Cooper EH, Thatcher N, Howell A: Activity of JM 9 in Advanced Ovarian Cancer: A phase I-II Trial. Cancer Treatment Report 69: 409, 1985

    Google Scholar 

  80. Blessing WP, Blessing JA, Hatch K, Disaia PJ: A phase II study of CHIP in advanced squamous cell carcinoma of the cervix (a Gynaecologic Oncology Group Study). Invest New Drugs 4: 181, 1986

    Google Scholar 

  81. Presnov MA, Konovalova AL, Kozlov AM, Brovtsyn VK, Romanova LF: The antitumor activity of oxoplatinum. Neoplasma 32: 73, 1985

    Google Scholar 

  82. Brandon RJ, Dabrowiak JC: Synthesis, characterisation and properties of a group of platinum (IV) complexes. J Med Chem 27: 861, 1984

    Google Scholar 

  83. Narayanan VL, Wolpert-De Filippes MW, Haugwitz RD: European Patent: 0154589A, 1985

  84. Craciunescu D, Ghirvu C, Doadrio Lopez A: Structure-antitumor activity relationship for new analogs of the cisdichloro (1, 2, diaminocyclohexane) platinum (II) complex. Biological Trace Element Research 5: 517, 1983

    Google Scholar 

  85. Kuroda R, Neidle S, Ismail IM, Sadler PJ: X-ray crystal and molecular structure of cis (N, N′) trans (O,O′)-Bis-(2-amine ethanolato)-cis-dichloroplatinum (IV) dihydrate. The relationship of antitumour activity to ring closure. JCS Dalton: 823, 1983

  86. Kuroda R, Neidle S, Ismail IM, Sadler PJ: Crystal and molecular structure of three isomers of dichlorodiammi-nedihydroxoplatinum (IV): cis-trans isomerisation on recrystallisation from water. Inorg Chem 22: 3620, 1983

    Google Scholar 

  87. Rotondo E, Fimiani V, Cavallaro A, Ainis T: Does the antitumoral activity of platinum (IV) derivatives result from their in vivo reduction. Tumori 69: 31, 1983

    Google Scholar 

  88. Barnard CFJ, Hydes PC, Griffith WP, Mills OS: A stable platinum complex perhydrate adduct: Crystal structures of cis, trans [PtCl2(OH)2(2-NH2Pr)2]. 0.5H2O2 and water and N, N-dimethylacetamide adducts. J Chem Res M: 2801, 1983

  89. Gmelins Handbuch Der Anorganischem Chemie, 8th Ed, No 68, Platinum

  90. Vollano JF, Blatter EE, Dabrowiak JC: DNA breakage by a perhydrate complex of cis, cis, trans-Pt (IV) Cl2 (NH3)2(OH)2. J Am Chem Soc 106: 2732, 1984

    Google Scholar 

  91. Blatter EE, Vollano JF, Krishnan BS, Dabrowiak JC: Platinum (IV) antitumor agents. Progr Clin Biol Res 172: 185, 1985

    Google Scholar 

  92. Blatter EE, Vollano JF, Krishnan BS, Dabrowiak JC: Interaction of the antitumour agents cis, cis, trans [Pt ((CH3)2CHNH2)2Cl2(OH)2] and cis, cis, trans [Pt((CH3)2CHNH2)2Cl4] and their reduction products with PM2 DNA. Biochemistry 23: 4817, 1984

    Google Scholar 

  93. Mong S, Eubanks PC, Prestayko AW, Crooke ST: Characterisation of in vitro deoxyribonucleic acid breakage and cross linking induced by bis(isopropylamine) trans-dihydroxy-cis-dichloroplatinum (IV). Biochemistry 21: 3174, 1982

    Google Scholar 

  94. Mong S, Huang AW, Prestayko AW, Crooke ST: Effects of second generation platinum analogs on isolated PM-2 DNA and their cytotoxicity in vitro and in vivo. Cancer Res 40: 3318, 1980

    Google Scholar 

  95. Mong S, Strong JE, Busch JA, Crooke ST: Use of covalently closed circular DNA for pre-screening of antitumour immunoglobulins that specifically inhibit DNA synthesis of mouse tumour cells. Antimicrob Agents Chemother 16: 398, 1979

    Google Scholar 

  96. Bocian E, Laverick M, Nias AHW: The mode of action of cis dichlorobis (isopropylamine) trans (dihydroxyl) platinum (IV) (CHIP) studied by the analysis of chromosome aberration production. Br J Cancer 47: 503, 1983

    Google Scholar 

  97. Nias AHW, Laverick M, Szumiel I. In: Karcher KH (ed) Progress in Radiooncology, Raven Press, New York, 1982, 2: 213

    Google Scholar 

  98. Klossa J: European Patent: 0054215, 1981

  99. Kroeger H, Dietrich AER, Gratz R, Klosa J: Cofplaton, a new platinum compound with antitumor activity. Proc 13th Int Congr Chemother 16: 284, 1983

    Google Scholar 

  100. Cramer RE: US Patent: 4, 325, 950, 1982

  101. Macquet JP, Beauchamp AL: Structure of a platinum (II) complex with morphine. Inorg Chim Acta 91: L25, 1984

  102. Pasini A, Bersanetti E, Zunino F, Savi G: Antitumor complexes of platinum with carrier molecules. I. Sulfadiazene derivatives of platinum (II). Inorg Chim Acta 80: 99, 1983

    Google Scholar 

  103. Farrell NP, Williamson J, McLaren DJM: Trypanocidal and antitumour activity of platinum-metal and platinum-metal-drug dual function complexes. Biochem Pharmacol 33: 961, 1984

    Google Scholar 

  104. Lippard SJ, Bowler BE: European Patent: 01633161A, 1985

  105. Pasini A, Zunino F, Tofanetti O, Gandolfi G, Tognella S: European Patent: 0170290A, 1986

  106. Wappes B, Jennerwein M, Von Angerer E, Schoenenberger H, Engel J, Berger M, Wrobel K-H: Dichloro [1,2-bis(4-hydroxyphenyl) ethylene diamino complexes]. An approach to develop compounds with a specific effect on the hormone dependent mannary carcinoma. J Med Chem 27: 1280, 1984

    Google Scholar 

  107. Schoenenberger H, Wappes B, Jennerwein M, Berger M: Development of selectively acting platinum complexes. Cancer Treatment Reviews 11: 125, 1984

    Google Scholar 

  108. Schoenenberger H, Wappes B, Jennerwein M, Von Angerer E, Engel JD: European Patent: 011 6955A, 1984

  109. Hurwitz E, Kashi R, Wilchek M: Platinum complexed antitumour immunoglobulins that specifically inhibit DNA synthesis of mouse tumour cells. J Nat Canc Inst 69: 47, 1982

    Google Scholar 

  110. Arnon R, Wilcheck M, Sela M, Schechter B: European Patent: 0099133A, 1984

  111. Smith GD, Brown DS, Bernstein P, Weller JE: European Patent: 0111388A, 1984

  112. Sears B: European Patent: 0113508A, 1984

  113. Ash PS, Hider RC: European Patent: 0007714B, 1983

  114. Freise J, Mueller WH, Magerstedt P, Schmoli HJ: Pharmacokinetics of liposome encapsulated. Cisplatin in rats. Arch Int Pharmacodyn 258: 180, 1982

    Google Scholar 

  115. Sur B, Ray RR, Sur P, Roy DK: Effect of liposomal encapsulation of cis-platinum diammino dichloride in the treatment of Ehrlich ascites carcinoma. Oncology 40: 372, 1983

    Google Scholar 

  116. Hecquet B, Fournier C, Depadt G, Cappelaere P: Preparation and release kinetics of microencapsulated cisplatin with ethylcellulose. J Pharm Pharmacol 36: 803, 1984

    Google Scholar 

  117. Yolles S: US Patent: 4, 419, 340, 1983

  118. Turkevich J, Burchenal JH: US Patent: 4, 376, 782, 1983

  119. Alston DR, Stoddart JF, Williams DJ: The isolation and X-ray crystal structure of an adduct formed between 18-Crown 6 and Cisplatin. J Chem Soc Chem Commun: 532, 1985

  120. Alston DR, Lilley TH, Stoddart JF: The binding of 1,1 cyclobutanedicarboxylato diammine platinum (II) by α-cyclodextrin in aqueous solution. J Chem Soc Chem Commun: 1600, 1985

  121. Alston DR, Slawin AMZ, Stoddart JF, Williams DJ: The X-ray crystal structure of a 1:1 adduct between α-cyclodextrin and diammine 1,1 cyclobutanedicarboxylato platinum (II). J Chem Soc Chem Commun: 1602, 1985

  122. Heimberger J, Keller JH, WO Patent 85/03078, 1985

  123. Douple EB: The use of platinum chemotherapy to potentiate radiation. Platinum Metals Review 29: 120, 1985

    Google Scholar 

  124. O'Hara JA, Douple EB, Richmond RC, presented at ‘Conference on Chemical Modifiers of Cancer Treatment’ (in press) 1986

  125. Sadler PJ, Coulson CJ: GB Patent: 2093, 451A, 1982

  126. Adams GE, Stratford IJ, Ahmed I: GB Patent: 2131020A, 1984

  127. Abrams M, Picker DH, Teicher BA: European Patent: 0186363A, 1986

  128. Bergquist BL, Chang JC: US Patent: 4, 490, 543, 1984

Download references

Author information

Authors and Affiliations

  1. Johnson Matthey Technology Centre, Reading, United Kingdom

    Paul C. Hydes & Michael J. H. Russell

Authors
  1. Paul C. Hydes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J. H. Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for offprints: Johnson Matthey Technology Centre, Blount's Court, Sonning Common, Reading, RG4 9NH, United Kingdom

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hydes, P.C., Russell, M.J.H. Advances in platinum cancer chemotherapy. Cancer Metast Rev 7, 67–89 (1988). https://doi.org/10.1007/BF00048279

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00048279

Key words

Search

Navigation